Recombinant activated factor VII for massive hemoptysis in patients with cystic fibrosis

Chest

Volumn 136, Issue 1, 2009, Pages 277-281

  Lau, Edmund M T ^a   Yozghatlian, Veronica ^a   Kosky, Chris ^a   Moriarty, Carmel ^a   Dentice, Ruth ^a   Waugh, Richard ^a   Torzillo, Paul J ^a   Bye, Peter T ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; HEMOSTATIC AGENT; MEROPENEM; RECOMBINANT ACTIVATED FACTOR VII; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANAMNESIS; ARTERY DILATATION; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; CASE REPORT; CLINICAL FEATURE; CYSTIC FIBROSIS; ERYTHROCYTE CONCENTRATE; FEMALE; HEMODYNAMICS; HEMOPTYSIS; HEMOSTASIS; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY FAILURE; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; TRACHEOSTOMY;

EID: 67650835136     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2948     Document Type: Article

References (27)

1. Flume A, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729-738
2. Barben I, Ditchfield M, Carlin J, et al. Major haemoptysis in children with cystic fibrosis: a 20-year retrospective study. J Cyst Fibros 2003; 2:105-111
3. Brinson G, Noone O, Mauro M, et al. Bronchial artery embolisation for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998; 157:1951-1958
4. Antonelli M, Midulla F, Tancredi G, et al. Bronchial artery embolisation for the management of non-massive hemoptysis in cystic fibrosis. Chest 2002; 121:796-801
5. Barben J, Robertson D, Olinsky A, et al. Bronchial artery embolisation in young patients with cystic fibrosis. Radiology 2002; 224:124-130
6. Poyanli A, Acunas B, Rozanes I, et al. Endovascular therapy in the management of moderate and massive hemoptysis. Br J Radiol 2007; 80:331-336
7. Cacao M, Webert K. On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers. Semin Hematol 2008; 45(suppl):S68-S71
8. Goodnough L, Shander A. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol 2007; 14:504-509
9. Shidlow D, Taussig L, Knowles M. Cystic fibrosis foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993; 15:187-198
10. Hsu A. Thoracic embolotherapy for life-threatening hemoptysis: a pulmonologist's perspective. Respirology 2005; 10:138-143
11. Yoon W, Kim J, Kim Y, et al. Bronchial and nonbronchial systemic artery embolisation for life-threatening hemoptysis: a comprehensive review. Radiographics 2002; 22:1395-1409
12. Knott-Craig CJ, Oostuizen J, Rossouw G, et al. Management and prognosis of massive haemoptysis: recent experience with 120 patients. J Thorac Cardiovasc Surg 1993; 105:394-397
13. Betensley A, Yankaskas J. Factor VIIa for alveolar hemorrhage in microscopic polyangiitis. Am J Respir Crit Care Med 2002; 166:201-202
14. Yildirim H, Uggun I, Yalcin A, et al. Recombinant factor VIIa treatment for life-threatening hemoptysis. Respirology 2006; 11:652-654
15. Tien H, Gough M, Farrel R, et al. Successful use of recombinant activated factor VII in a patient with massive hemoptysis from a penetrating thoracic injury. Ann Thorac Surg 2007; 84:1373-1374
16. Hicks K, Peng D, Gakewski J. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30:975-978
17. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9(suppl):S147-S152
18. Macdonald J, Fraser J, Foot C, et al. Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia. Chest 2006; 130:577-579
19. Monroe D. Further understanding of recombinant activated factor VII mode of action. Semin Hematol 2008; 45(suppl):S7-S11
20. Monroe D, Hoffman M, Oliver J, et al. Platelet activity of high dose factor VIIa is independent of tissue-factor. Br J Haematol 1997; 99:542-547
21. Hoffman M, Monroe D, Roberts H. Activated factor VII activates factor IX and X on the surface of activated platelets: thoughts on the mechanism of action of high dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9(suppl):S61-S65
22. Stanworth S, Birchall J, Doree C, et al. Recombinant factor VIIa for prevention and treatment of bleeding in patients without hemophilia. Cochrane Database Syst Rev (database online). Issue 2, 2007
23. Bosch J, Thabut D, Bendsten F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomised double blinded trial. Gastroenterology 2004; 127:1123-1130
24. Maclaren R, Weber L, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion 2005; 45:1434-1442
25. Mayer S, Brun N, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785
26. Midathada M, Mehta P, Warner M, et al. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004; 121:124-137
27. Rodriguez-Merchan E, Rocino A, Ewenstein B, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004; 10(suppl):S50-S52